These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29264191)

  • 1. Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer.
    Hirata T; Park SC; Muldong MT; Wu CN; Yamaguchi T; Strasner A; Raheem O; Kumon H; Sah RL; Cacalano NA; Jamieson CHM; Kane CJ; Masuda K; Kulidjian AA; Jamieson CAM
    Asian J Urol; 2016 Oct; 3(4):229-239. PubMed ID: 29264191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
    Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
    J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.
    Godebu E; Muldong M; Strasner A; Wu CN; Park SC; Woo JR; Ma W; Liss MA; Hirata T; Raheem O; Cacalano NA; Kulidjian AA; Jamieson CA
    J Transl Med; 2014 Oct; 12():275. PubMed ID: 25278011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
    Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
    Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.
    Eswaraka J; Giddabasappa A; Han G; Lalwani K; Eisele K; Feng Z; Affolter T; Christensen J; Li G
    BMC Cancer; 2014 Oct; 14():742. PubMed ID: 25277255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.
    Ceci F; Castellucci P; Graziani T; Schiavina R; Chondrogiannis S; Bonfiglioli R; Costa S; Virgolini IJ; Rubello D; Fanti S; Colletti PM
    Clin Nucl Med; 2015 May; 40(5):e265-70. PubMed ID: 25783519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: Osteolytic versus osteoblastic.
    Reddington JA; Mendez GA; Ching A; Kubicky CD; Klimo P; Ragel BT
    Surg Neurol Int; 2016; 7(Suppl 13):S361-5. PubMed ID: 27274410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
    Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
    Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
    Wu TT; Sikes RA; Cui Q; Thalmann GN; Kao C; Murphy CF; Yang H; Zhau HE; Balian G; Chung LW
    Int J Cancer; 1998 Sep; 77(6):887-94. PubMed ID: 9714059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone.
    Lee Y; Schwarz E; Davies M; Jo M; Gates J; Wu J; Zhang X; Lieberman JR
    J Orthop Res; 2003 Jan; 21(1):62-72. PubMed ID: 12507581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel immunocompetent model of metastatic prostate cancer-induced bone pain.
    Liu Z; Murphy SF; Huang J; Zhao L; Hall CC; Schaeffer AJ; Schaeffer EM; Thumbikat P
    Prostate; 2020 Jul; 80(10):782-794. PubMed ID: 32407603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer.
    Fradet A; Sorel H; Depalle B; Serre CM; Farlay D; Turtoi A; Bellahcene A; Follet H; Castronovo V; Clézardin P; Bonnelye E
    PLoS One; 2013; 8(9):e75092. PubMed ID: 24069383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-tibial injection of human prostate cancer cell line CWR22 elicits osteoblastic response in immunodeficient rats.
    Andersen C; Bagi CM; Adams SW
    J Musculoskelet Neuronal Interact; 2003 Jun; 3(2):148-55. PubMed ID: 15758355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer metastases alter bone mineral and matrix composition independent of effects on bone architecture in mice--a quantitative study using microCT and Raman spectroscopy.
    Bi X; Sterling JA; Merkel AR; Perrien DS; Nyman JS; Mahadevan-Jansen A
    Bone; 2013 Oct; 56(2):454-60. PubMed ID: 23867219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET Tracer
    Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H
    Theranostics; 2017; 7(7):2048-2064. PubMed ID: 28656060
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
    Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
    Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal and spatial changes in bone mineral content and mechanical properties during breast-cancer bone metastases.
    Verbruggen ASK; McCarthy EC; Dwyer RM; McNamara LM
    Bone Rep; 2022 Dec; 17():101597. PubMed ID: 35754558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.